Here, we examined the effect of treatment with a recently synthetized first-in-class GSK-3β/HDAC dual inhibitor, Compound 11 (C11) [29], to rescue CDD-related phenotypes in in vitro and in vivo models of CDD. Here, HDAC9 is linked to craniodiaphyseal dysplasia.